One shot enough? thai kids' hepatitis a immunity tested years later
NCT ID NCT07032610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 60 healthy Thai children and teens who received a single dose of a live-attenuated hepatitis A vaccine about a year ago. Researchers want to see how many still have protective antibodies and at what levels. The goal is to understand long-term immunity and help decide if this vaccine should be added to Thailand's routine immunization schedule.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Healthy Thai children and adolescents age 18 months to 20 years who received a single dose of L-HAV vaccine in the previous RCT study.
- Ages
-
18 months to 20 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Thai children and adolescents who previously participated in the previous RCT study * Previously randomized to receive one dose of L-HAV vaccine within the past 1 year (+/- 3 months) * Participants and/or caregivers gives written inform consent/assent form Exclusion Criteria: * History of acute illness within 4 weeks prior to study enrollment * Has a history of illness or a diagnosis consistent with hepatitis A after receiving the live attenuated hepatitis A vaccine as part of participation in a previous research study * Has a history of receiving any additional hepatitis A vaccine after participating in the previous research study * Presence of fever (body temperature ≥38.0°C), jaundice, or yellowing of the eyes within 4 weeks prior to study enrollment * Have any condition that, in the opinion of the site investigator, would compromise the subject's ability to participate in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hepatitis A are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Pediatrics, Faculty of Medicine, Chiang Mai University
Chiang Mai, 50200, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vaccine shield transplant patients from shingles?
- Tweets that tell a story: a new approach to boosting HPV vaccination
- Which COVID-19 shot causes fewer side effects? new study compares novavax and pfizer
- New vaccine for moms could shield babies from whooping cough
- Booster shot hope: extra hepatitis a vaccine studied for thai kids
- Can a common bile acid pill speed recovery from hepatitis?